GlaxoSmithKline Completes Acquisition of Human Genome Sciences
03 Agosto 2012 - 9:00AM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK), a research-based
pharmaceutical and healthcare company, said Friday it has completed
its acquisition of Human Genome Sciences (HGSI) for 3.6 billion
dollars on an equity basis, or $3 billion net of cash and debt.
MAIN FACTS:
-All outstanding shares of HGS were acquired for $14.25 per
share in cash.
-Subsequent offering period for GSK's tender offer for HGS
shares expired at 2100 GMT, on Aug. 2.
-Glaxo shares closed in London Thursday at 1487 pence valuing
the company at 74.16 billion pounds.
-Write to Ian Walker at ian.walker@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Human Genome Sciences, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Human Genome Sciences Inc. Articoli Notizie